ストックスクリーナーアプリを入手
3.70
3.35%
0.12
プレマーケット:
3.66
-0.04
-1.08%
前日終値:
$3.58
開ける：
$3.52
24時間の取引高:
19.08M
Relative Volume:
0.70
時価総額：
$1.98B
収益：
$66.41M
当期純損益:
$-559.78M
株価収益率:
-3.0777
EPS:
-1.2022
ネットキャッシュフロー:
$-328.09M
1週間 パフォーマンス:
+2.49%
1か月 パフォーマンス:
-1.07%
6か月 パフォーマンス:
+5.41%
1年 パフォーマンス:
-38.74%
1日の値動き範囲:
$0.00
$0.00
1週間の範囲:
$3.45
$3.76
52週間の値動き範囲:
$2.77
$6.50
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
名前
Recursion Pharmaceuticals Inc
セクター
電話
(385) 269-0203
住所
41S RIO GRANDE STREET, SALT LAKE CITY
Compare RXRX vs VRTX, REGN, MRNA, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
3.70 | 1.98B | 66.41M | -559.78M | -328.09M | -1.2022 |
VRTX
Vertex Pharmaceuticals Inc
|
523.93 | 132.80B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.02 | 82.88B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
200.10 | 79.89B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
873.71 | 54.94B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
377.63 | 42.72B | 5.76B | 514.49M | 1.10B | 4.4813 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-17 | アップグレード | JP Morgan | Neutral → Overweight |
| 2025-07-03 | 再開されました | Morgan Stanley | Equal-Weight |
| 2023-05-22 | 開始されました | Morgan Stanley | Equal-Weight |
| 2023-03-16 | 開始されました | Needham | Buy |
| 2022-09-16 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-03-04 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | 開始されました | Berenberg | Buy |
| 2021-05-11 | 開始されました | BofA Securities | Buy |
| 2021-05-11 | 開始されました | Goldman | Neutral |
| 2021-05-11 | 開始されました | JP Morgan | Neutral |
| 2021-05-11 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Recursion Pharmaceuticals Inc (RXRX) 最新ニュース
Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing - Zacks Investment Research
Recursion Prices 61.54M-Share Offering at $3.25; Underwriters Led by Leerink, Goldman - TradingView
Form 424B5 Recursion Pharmaceuticals Inc For: 15 October By Investing.com - Investing.com Canada
Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock - Yahoo Finance
Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note - Zacks Investment Research
Tempus AI Expands Strategic Collaborations to Drive Future Growth - Zacks Investment Research
Director Hershberg sells $125k in Recursion Pharmaceuticals stock By Investing.com - Investing.com South Africa
Director Hershberg sells $125k in Recursion Pharmaceuticals stock - Investing.com
Director Hershberg sells $125k in Recursion Pharmaceuticals stock By Investing.com - Investing.com UK
Under a trading plan, Recursion (RXRX) director sells 50,000 shares averaging $4.84 each. - Stock Titan
A director sells 25,000 shares at $5 after exercising options at $2.22 at Recursion (RXRX). - Stock Titan
Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors - Zacks Investment Research
Recursion Pharmaceuticals Director Hershberg to Sell 25,000 Shares via Option Exercise - Kalkine Media
Recursion Pharmaceuticals, Inc.Class A Common Stock (Nasdaq:RXRX) Stock Quote - FinancialContent
A 50,000-share sale is proposed by director Blake C. Borgeson at Recursion (RXRX). - Stock Titan
25,000 shares worth $125K are proposed for sale by Recursion (RXRX) director Robert Hershberg. - Stock Titan
A $0-per-share award brings Zavain Dar's direct Recursion (RXRX) holdings to 245,371 shares. - Stock Titan
Dean Y. Li receives 3,378 Recursion (RXRX) shares under its Outside Director Compensation Policy. - Stock Titan
Recursion Pharmaceuticals (RXRX) CFO’s 5,396-share move wasn’t a sale - Stock Titan
Recursion Pharma CEO Najat Khan sells $78,822 in stock By Investing.com - Investing.com South Africa
Recursion Pharma CEO Najat Khan sells $78,822 in stock By Investing.com - Investing.com Australia
Recursion Pharmaceuticals (RXRX) CEO and President Najat Khan Sells 22,408 Shares - GuruFocus
Recursion Pharma CEO Najat Khan sells $78,822 in stock - Investing.com
Recursion Pharma CEO Najat Khan sells $78,822 in stock - Investing.com
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Khan Najat - Moomoo
Recursion Pharmaceuticals CEO Najat Khan Sells 22,408 Shares Under 10b5-1 Plan - Kalkine Media
Recursion Pharmaceuticals (NASDAQ:RXRX) Trades Active As Small-Caps Wobble - Kalkine Media
Recursion (NASDAQ: RXRX) CEO sells 22K shares under preset plan - Stock Titan
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today - Yahoo Finance
Recursion Pharmaceuticals Tokenized Stock (Ondo) price today, RXRXon to USD live price, marketcap and chart - CoinMarketCap
Recursion Pharmaceuticals Stock Short Interest Falls to 34.79% - Moomoo
Recursion Pharmaceuticals Stock Short Interest Falls to 34.79% - Quiver Quantitative
Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
2 Beaten-Down Stocks to Avoid Right Now - theglobeandmail.com
AI in Pharmaceutical Market to Hit USD 48.43 Billion by 2035, Growing at 31.76% CAGR – SNS Insider - GlobeNewswire Inc.
Drug Repurposing Market to Reach USD 50.91 Billion by 2035, Expanding at 3.93% CAGR | SNS Insider - GlobeNewswire Inc.
Penny Stocks To ResearchSeptember 6th - MarketBeat
Penny Stocks To Follow NowSeptember 5th - MarketBeat
RXRX Tightens Spending As AI Drug Platform Gains Traction - timothysykes.com
RXRX Tightens Cash Burn As AI Drug Pipeline Advances - StocksToTrade
RXRX Tightens Costs As AI Drug Pipeline Advances - timothysykes.com
Why Is Recursion Pharmaceuticals (RXRX) Up 8.2% Since Last Earnings Report? - Yahoo Finance
$Recursion Pharmaceuticals (RXRX.US)$ - Moomoo
Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook? - The Globe and Mail
Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook? - Eastern Progress
Recursion Pharmaceuticals director Blake Borgeson sells $100,200 in stock By Investing.com - Investing.com Australia
Recursion Pharmaceuticals director Blake Borgeson sells $100,200 in stock By Investing.com - Investing.com Canada
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Borgeson Blake - Moomoo
Recursion Pharmaceuticals Stock (RXRX) Opinions on AI Drug Discovery Pipeline - Quiver Quantitative
Recursion (NASDAQ: RXRX) director sells 30,000 shares in planned trade - Stock Titan
Recursion Pharmaceuticals Inc (RXRX) 財務データ
収益
当期純利益
現金流量
EPS
Recursion Pharmaceuticals Inc (RXRX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Borgeson Blake | Director |
Oct 06 '26 |
Proposed Sale |
4.84 |
50,000 |
242,000 |
0 |
| HERSHBERG ROBERT | Director |
Oct 06 '26 |
Proposed Sale |
5.00 |
25,000 |
125,000 |
0 |
| HERSHBERG ROBERT | Director |
Oct 06 '26 |
Option Exercise |
2.22 |
25,000 |
55,500 |
187,156 |
| HERSHBERG ROBERT | Director |
Oct 06 '26 |
Sale |
5.00 |
25,000 |
125,000 |
162,156 |
| Najat Khan | Officer |
Sep 08 '26 |
Proposed Sale |
3.52 |
22,408 |
78,822 |
0 |
| Khan Najat | CEO and President |
Sep 08 '26 |
Sale |
3.52 |
22,408 |
78,822 |
2,072,890 |
| Borgeson Blake | Director |
Sep 01 '26 |
Proposed Sale |
3.34 |
30,000 |
100,200 |
0 |
| Borgeson Blake | Director |
Sep 01 '26 |
Sale |
3.34 |
30,000 |
100,200 |
6,158,287 |
| Gibson Christopher | Former Director |
Aug 21 '26 |
Proposed Sale |
3.39 |
77,290 |
262,013 |
0 |
| Gibson Christopher | Former Director |
Aug 20 '26 |
Proposed Sale |
3.40 |
75,000 |
255,000 |
0 |
3.65%
0.80%
大文字化:
|
ボリューム (24 時間):